menu
    • menu
    [{"orgOrder":0,"company":"Rutgers, The State University of New Jersey","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Besifloxacin Hydrochloride","moa":"Bacterial DNA gyrase","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Rutgers, The State University of New Jersey","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Rutgers, The State University of New Jersey \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"6","companyTruncated":"Rutgers, The State University of New Jersey \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Cornea Consultants Of Nashville","sponsor":"SCRI Development Innovations, LLC | Bausch & Lomb Incorporated","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Besifloxacin Hydrochloride","moa":"Bacterial DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cornea Consultants Of Nashville","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Cornea Consultants Of Nashville \/ SCRI Development Innovations, LLC | Bausch & Lomb Incorporated","highestDevelopmentStatusID":"8","companyTruncated":"Cornea Consultants Of Nashville \/ SCRI Development Innovations, LLC | Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Besifloxacin Hydrochloride","moa":"Bacterial DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Besifloxacin Hydrochloride","moa":"Bacterial DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Besifloxacin Hydrochloride","moa":"Bacterial DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Besifloxacin Hydrochloride","moa":"Bacterial DNA gyrase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"John, George, M.D.","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Besifloxacin Hydrochloride","moa":"Bacterial DNA gyrase","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch & Lomb Incorporated \/ John, George, M.D.","highestDevelopmentStatusID":"11","companyTruncated":"Bausch & Lomb Incorporated \/ John, George, M.D."}]

    Find Clinical Drug Pipeline Developments & Deals for Besifloxacin Hydrochloride

    Menu

    Besifloxacin Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cornea Consultants Of Nashville

                            Country arrow
                            BOS Manchester
                            Not Confirmed

                            Cornea Consultants Of Nashville

                            Country arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Besifloxacin Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : SCRI Development Innovations, LLC | Bausch & Lomb Incorporated

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers.

                            Details : Besifloxacin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Corneal Ulcer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 27, 2013

                            Lead Product(s) : Besifloxacin Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : SCRI Development Innovations, LLC | Bausch & Lomb Incorporated

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bausch & Lomb Incorporated

                            Canada arrow
                            BOS Manchester
                            Not Confirmed

                            Bausch & Lomb Incorporated

                            Canada arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Besifloxacin Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conj...

                            Details : Besifloxacin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Conjunctivitis, Bacterial.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 04, 2012

                            Lead Product(s) : Besifloxacin Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Bausch & Lomb Incorporated

                            Canada arrow
                            BOS Manchester
                            Not Confirmed

                            Bausch & Lomb Incorporated

                            Canada arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Besifloxacin Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase IV

                            Sponsor : John, George, M.D.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute Blepha...

                            Details : Besifloxacin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Blepharitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 23, 2011

                            Lead Product(s) : Besifloxacin Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase IV

                            Sponsor : John, George, M.D.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Rutgers, The State University of New Jersey

                            Country arrow
                            BOS Manchester
                            Not Confirmed

                            Rutgers, The State University of New Jersey

                            Country arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Besifloxacin Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Bausch & Lomb Incorporated

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy Study of Besivanceâ„¢ for Treatment of Congenital Nasolacrimal Duct Obstruction in Chi...

                            Details : Besifloxacin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lacrimal Duct Obstruction.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 09, 2011

                            Lead Product(s) : Besifloxacin Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Bausch & Lomb Incorporated

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Bausch & Lomb Incorporated

                            Canada arrow
                            BOS Manchester
                            Not Confirmed

                            Bausch & Lomb Incorporated

                            Canada arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Besifloxacin Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunct...

                            Details : Besivance (Besifloxacin) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Conjunctivitis, Bacterial.

                            Product Name : Besivance

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 06, 2011

                            Lead Product(s) : Besifloxacin Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Bausch & Lomb Incorporated

                            Canada arrow
                            BOS Manchester
                            Not Confirmed

                            Bausch & Lomb Incorporated

                            Canada arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Besifloxacin Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety of Besivanceâ„¢ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle

                            Details : Besivance (Besifloxacin) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Conjunctivitis, Bacterial.

                            Product Name : Besivance

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 05, 2010

                            Lead Product(s) : Besifloxacin Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Bausch & Lomb Incorporated

                            Canada arrow
                            BOS Manchester
                            Not Confirmed

                            Bausch & Lomb Incorporated

                            Canada arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Besifloxacin Hydrochloride

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered ISV-403 for 5 Days

                            Details : Besifloxacin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 11, 2010

                            Lead Product(s) : Besifloxacin Hydrochloride

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth